"Dec. 24, 2012 -- Colorado Springs high school junior Morgan Smith can't remember a time when he didn't have life-threatening food allergies.
The 16-year-old had his first reaction to peanut butter at 9 months of age when he broke out in hiv"...
Qnasl Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Qnasl (beclocmethasone dipropionate) nasal aerosol is used to treat nasal symptoms associated with seasonal and perennial allergic rhinitis for patients who are 12 years of age or older. Qnasl nasal aerosol is a corticosteroid. Common side effects of Qnasl nasal aerosol include nasal discomfort, nosebleed, and headache.
The recommended dose of Qnasl nasal aerosol is 320 mcg per day divided into 2 nasal aerosol sprays per nostril once a day. There are no known drug interactions for Qnasl nasal aerosol. Tell your doctor all medications you use. Qnasl nasal aerosol should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when Qnasl nasal aerosol is administered to nursing mothers as some corticosteroids have been detected in human breast milk.
Our Qnasl (beclocmethasone dipropionate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Qnasl FDA Prescribing Information: Side Effects
Systemic and local corticosteroid use may result in the following:
- Epistaxis, nasal discomfort, nasal ulcerations, Candida albicans infection, and impaired wound healing [see WARNINGS AND PRECAUTIONS]
- Glaucoma and cataracts [see WARNINGS AND PRECAUTIONS]
- Hypercorticism, adrenal suppression, and growth reduction [see WARNINGS AND PRECAUTIONS, Use In Specific Populations]
- Immunosuppression [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults and Adolescents 12 Years of Age and Older
The safety data described below for adults and adolescents 12 years of age and older with seasonal or perennial allergic rhinitis are based on 4 placebo-controlled clinical trials of 2 to 6 weeks duration evaluating doses of beclomethasone nasal aerosol from 80 to 320 mcg once daily. These short-term trials included a total of 1394 patients with either seasonal or perennial allergic rhinitis. Of these, 575 (378 female and 197 male) received at least one dose of QNASL Nasal Aerosol, 320 mcg once daily and 578 (360 female and 218 male) received placebo. Patient ages ranged from 12 to 82 years and the racial distribution of patients was 81% white, 16% black, and 4% other.
Short-Term (2-6 Weeks) Trials
Less than 2% of patients in the clinical trials discontinued treatment because of adverse reactions with the rate of withdrawal among patients who received QNASL Nasal Aerosol similar to or lower than the rate among patients who received placebo. Table 1 displays the common adverse reactions ( ≥ 1% and greater than placebo-treated patients).
Table 1: Adverse Events With ≥ 1%
Incidence and Greater than Placebo in QNASL Nasal Aerosol-Treated Adult and
Adolescent Patients with Seasonal or Perennial Allergic Rhinitis in Controlled
Clinical Trials of 2 to 6 Weeks Duration (Safety Population)
|Adult and Adolescent Patients 12 Years of Age and Older|
|QNASL Nasal Aerosol 320 mcg
(N = 575) n (%)
(N = 578) n (%)
|Nasal Discomfort||30 (5.2)||28 (4.8)|
|Epistaxis||11 (19)||7 (1.2)|
|Headache||13 (2.3)||9 (1.6)|
Nasal ulcerations occurred in 2 patients treated with placebo and in 1 patient treated with QNASL Nasal Aerosol. There were no differences in the incidence of adverse reactions based on gender or race. Clinical trials did not have sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients.
Long-Term 52-Week Safety Trial
In a 52-week placebo-controlled long-term safety trial in patients with PAR, 415 patients (128 males and 287 females, aged 12 to 74 years) were treated with QNASL Nasal Aerosol at a dose of 320 mcg once daily and 111 patients (44 males and 67 females, aged 12 to 67 years) were treated with placebo. Of the 415 patients treated with QNASL Nasal Aerosol, 219 patients were treated for 52 weeks and 196 patients were treated for 30 weeks. While most adverse events were similar in type and rate between the treatment groups, epistaxis occurred more frequently in patients who received QNASL Nasal Aerosol (45 out of 415, 11%) than in patients who received placebo (2 out of 111, 2%). Epistaxis also tended to be more severe in patients treated with QNASL Nasal Aerosol. In 45 reports of epistaxis in patients who received QNASL Nasal Aerosol, 27, 13, and 5 cases were of mild, moderate, and severe intensity, respectively, while the reports of epistaxis in patients who received placebo were of mild (1) and moderate (1) intensity. Seventeen patients treated with QNASL Nasal Aerosol experienced adverse reactions that led to withdrawal from the trial compared to 3 patients treated with placebo. There were 4 nasal erosions and 1 nasal septum ulceration which occurred in patients who received QNASL Nasal Aerosol, and no erosions or ulcerations noted in patients who received placebo. No patient experienced a nasal septum perforation during the trial.
Pediatric Patients Aged 4 to 11 Years:
The safety data described below for pediatric patients 4 to 11 years of age with seasonal or perennial allergic rhinitis are based on 3 placebo-controlled clinical trials. These trials were 2 to 12 weeks in duration, evaluated doses of beclomethasone nasal aerosol 80 mcg to 160 mcg once daily and included a total of 1360 patients with either seasonal or perennial allergic rhinitis. Of these, 668 (312 female and 356 male) received at least one dose of QNASL Nasal Aerosol, 80 mcg once daily, 241 (116 female and 125 male) received QNASL Nasal Aerosol 160 mcg once daily, and 451 (203 female and 248 male) received placebo. The racial distribution of patients was 73% white, 20% black, and 6% other. Based on the results from the dose ranging trial, 80 mcg once daily was chosen as the dose in pediatric patients.
Less than 1.5% of patients in the clinical trials discontinued treatment because of adverse reactions with the rate of withdrawal among patients who received QNASL Nasal Aerosol 80 mcg once daily similar to or lower than the rate among patients who received placebo. Table 2 displays the common adverse reactions ( ≥ 2% and greater than placebo-treated patients). Additionally, epistaxis was reported at a rate of 4% for both QNASL Nasal Aerosol 80 mcg once daily and placebo treated patients.
Table 2: Adverse Events With ≥ 2% Incidence and
Greater than Placebo in QNASL Nasal Aerosol-Treated Pediatric Patients with
Seasonal or Perennial Allergic Rhinitis in Controlled Clinical Trials of 2 to
12 weeks Duration (Safety Population)
|Pediatric Patients 4 to 11 Years of Age|
|QNASL Nasal Aerosol 80 mcg
(N=668) n (%)
(N=451) n (%)
|Headache||23 (3.4)||15 (3.3)|
|Pyrexia||19 (2.8)||7 (1.6)|
|Upper respiratory tract infection||17 (2.5)||8 (1.8)|
|Nasopharyngitis||15 (2.2)||6 (1.3)|
In addition to adverse reactions reported from clinical trials for QNASL Nasal Aerosol, the following adverse events have been reported during postmarketing use of QNASL Nasal Aerosol or other intranasal and inhaled formulations of beclomethasone dipropionate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to beclomethasone dipropionate or a combination of these factors.
QNASL Nasal Aerosol: sneezing, burning sensation
Intranasal beclomethasone dipropionate: Nasal septal perforation, glaucoma, cataracts, loss of taste and smell, and hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported following intranasal administration of beclomethasone dipropionate.
Inhaled beclomethasone dipropionate: Hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, and bronchospasm have been reported following the oral inhalation of beclomethasone dipropionate.
Read the entire FDA prescribing information for Qnasl (Beclomethasone Dipropionate Nasal Aerosol)
Additional Qnasl Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.